

TMS (4891 TSE Growth) - - - - - November 30, 2022**Drug discovery bioventure originated by Tokyo University of Agriculture and Technology**

This report is an English translation of part of the report issued on November 25, 2022.
For inquiries concerning the report, please contact info@stock-r.org

[4891 TMS Sector : Pharmaceutical]

Fiscal Year	Net sales (mn yen)	YoY (%)	Operating profit (mn yen)	YoY (%)	Ordinary profit (mn yen)	YoY (%)	Profit (mn yen)	YoY (%)	EPS (yen)	BPS (yen)	DPS (yen)
Feb.2021	-	-	-721	-	-720	-	-722	-	-171.5	-403.7	0.0
Feb.2022	1,946	-	1,135	-	1,079	-	1,076	-	53.4	74.1	0.0
Feb.2023 f	-	-	-896	-	-1,230	-	-1,230	-	-36.2	-	0.0

Note: Non-consolidated basis. Figures for the fiscal year ending February 2023 are the company's forecasts.
It conducted 1-to-40 stock split on September 21, 2021. Per share indices are adjusted retroactively.

Drug Discovery Bioventure

TMS was founded in 2005 for the purpose of commercializing the pharmaceutical seeds of the Department of Fermentation Science and Technology (Professor Keiji Hasumi) of Tokyo University of Agriculture and Technology. It is a drug discovery-based bioventure whose objective is the development of drugs for the global pharmaceutical market.

Drug Development Using SMTP Compounds

Currently, the company is developing pharmaceuticals that utilize the anti-inflammatory effects of staplabin, a compound produced by *Stachybotrys microspora*, a type of black mold, and SMTP (stachybotrys microspora triphenyl phenol) compounds, which consist of about 60 derivatives, and the prothrombolytic effects of certain SMTP compounds.

Development Pipeline

The current pipeline consists of two compounds, TMS-007 and TMS-008, with TMS-009 as a backup compound for TMS-008.

TMS-007 has anti-inflammatory and prothrombolytic effects and is being developed for the treatment of acute ischemic strokes. It is superior in terms of efficacy and safety to existing drugs, as evidenced by its acting only at the site of a blood clot and not having intracranial hemorrhage as a side effect. The phase 2a clinical trial in Japan was completed in August 2021. In May 2021, the product was licensed out to Biogen, who will be responsible for its future development and marketing. The company could recognize up to \$335 million in milestone revenue on TMS-007, as well as post-launch royalties from the high single-digits to 10% to 15% of drug net sales until the expiration of development patent rights or six years after the launch of sales, whichever comes later.

TMS-008 is presently in the preclinical stage for the indications of acute kidney injury and cancer cachexia, and is aiming to enter clinical trials for acute kidney injury in fiscal year ending February 2024. The company intends to license the drug following confirmation of its efficacy in humans in the first-phase clinical trials.

TMS (4891 TSE Growth) - - - - - November 30, 2022**Financial Statements**

Statement of income	Fiscal Year	Feb.2021		Feb.2022		Six months to Aug. 2022	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Operating income		-	-	1,946	100.0	-	-
Operating expenses		721	-	810	41.6	268	-
Operating profit		-721	-	1,135	58.3	-268	-
Non-operating income		0	-	38	-	0	-
Non-operating expenses		-	-	-	-	200	-
Ordinary profit		-720	-	1,079	55.4	-469	-
Profit before income taxes		-721	-	1,079	55.4	-469	-
Net profit		-722	-	1,076	55.3	-468	-

Balance sheet	Fiscal Year	Feb.2021		Feb.2022		Aug. 2022	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets		1,212	99.9	2,722	99.4	2,056	99.0
Cash and deposits		1,106	91.2	2,598	94.9	1,993	96.0
Accounts receivable-trade		-	-	-	-	-	-
Inventories		-	-	-	-	0	0.0
Non-current assets		0	0.0	16	0.6	21	1.0
Property, plant and equipment		0	0.0	4	0.1	10	0.5
Intangible assets		-	-	4	0.1	3	0.1
Investments and other assets		0	0.0	8	0.3	7	0.3
Total assets		1,213	100.0	2,739	100.0	2,077	100.0
Current liabilities		86	7.1	285	10.4	92	4.4
Accounts payable - trade		-	-	-	-	-	-
Non-current liabilities		-	-	1	0.0	-	-
Net assets		1,126	92.8	2,453	89.6	1,984	95.5
Owners' equity		1,126	92.8	2,453	89.6	1,984	95.5

Statement of cash flows	Fiscal Year	Feb.2021	Feb.2022	Six months to Aug. 2022
		(mn yen)	(mn yen)	(mn yen)
Cash flows from operating activities		-737	1,261	-364
Depreciation		4	0	2
Cash flows from investing activities		0	-16	-6
Cash flows from financing activities		1,101	246	-233
Dividends paid		-	-	-
Net increase in cash and cash equivalents		362	1,491	-604
Cash and cash equivalents		1,106	2,598	1,993

Note: Non-consolidated

Source: Prepared by Stock Research Center based on the notifiable prospectus.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■Supporting Members

Tokyo Stock Exchange, Inc.	SMBC Nikko Securities Inc.	Daiwa Securities Co. Ltd.
Nomura Securities Co., Ltd.	Mizuho Securities Co., Ltd.	Ernst & Young ShinNihon LLC
KPMG AZSA LLC	ICMG Co., Ltd.	Grant Thornton Taiyo LLC
Deloitte Touche Tohmatsu LLC	SBI SECURITIES Co., Ltd.	BDO Sanyu
Pricewaterhouse Coopers Kyoto	J Trust Global Securities Co., Ltd.	Ichiyoshi Securities Co., Ltd.
A&A Partners	GYOSEI & CO.	Avantia G.P.
TAKARA PRINTING CO., LTD.	PRONEXUS INC.	Japan Securities Dealers Association
The Securities Analysts Association of Japan		

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.